More Business Wire
View Older Stories View Newer Stories-
Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO
-
Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage
-
Abyan Capital Launches Shariah-Compliant, Self-Directed Access to US Markets with Alpaca
-
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
-
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
-
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
-
AM Best to Host Annual MENA Insurance Market Briefing in Dubai
-
Lone Star Announces Sale of Xella to Holcim
-
Bass Pro Shops Ranked Highest in 2025 Boat Industry Study Measuring Response to Sales Customer Calls
-
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products
-
AM Best to Participate at 2025 Shanghai International Reinsurance Conference
-
AM Best to Host Market Briefing at 2025 Singapore International Reinsurance Conference
-
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
-
The Republic of Korea Selects L3Harris for Airborne Early Warning and Control Aircraft Program
-
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
-
FreightTracker Receives Strategic Growth Investment from Arcadea Group
-
American Airlines and Citi Launch the Citi / AAdvantage Globe Mastercard
-
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the
-
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
-
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-O
-
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
-
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative brea
-
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
-
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy
-
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
-
Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025
-
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
-
DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom
-
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
-
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
-
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
-
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
-
Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
-
13th Annual Energy Day Festival Sparks STEM Interest Among Houston Students
-
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy
-
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer W
-
ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
-
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Tri
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTI
-
Infrrd Announces the Official Launch of Ally: The First Agentic AI Workforce for Mortgage Auditing
-
University of Phoenix College of Social and Behavioral Sciences Leadership Publishes White Paper on Trauma-Informed Education
-
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical O
-
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Ba
-
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
-
Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress
-
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
-
Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
-
CORRECTING and REPLACING Alliant Insurance Services Expands Transportation Risk and Cross-Border Expertise in Texas through Strategic Acquisition and Key Hires
-
Light & Wonder Statement on NV Legal Proceedings
